{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:18:40Z","timestamp":1788812320135,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis is associated with increased cardiovascular risk, possibly mediated by inflammation-induced hemostatic dysregulation and hypercoagulability. However, these changes are often difficult to detect with conventional markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess hypercoagulability in patients with psoriasis using the Overall Hemostatic Potential (OHP) test, a global integrative test for coagulation and fibrinolysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We studied 80 psoriasis patients (54 men, 26 women, aged 30\u201345\u202fyears) receiving effective topical or systemic treatments (methotrexate, adalimumab, secukinumab or guselkumab) and compared them with 20 healthy controls. We measured OHP, its components \u2014 overall coagulation potential (OCP) and overall fibrinolytic potential (OFP) and selected hemostatic markers (platelet count, mean platelet volume, platelet-to-lymphocyte ratio, P-selectin, D-dimer and fibrinogen).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Psoriasis patients had significantly higher OHP levels, primarily due to decreased OFP, while OCP levels were comparable to the control group \u2014 indicating a hypercoagulable state due to impaired fibrinolysis. Other conventional hemostatic markers showed no significant differences. OHP and OFP correlated with residual inflammatory activity, BMI, waist circumference, visceral adiposity and fibrinogen levels, suggesting a relationship between subclinical inflammation, metabolic parameters and hemostatic imbalance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The OHP test reveals a hypercoagulable state in psoriasis patients even in the absence of abnormal standard coagulation markers. OHP could be a practical and sensitive tool to stratify cardiovascular risk in psoriasis, especially in patients with concomitant metabolic disease or persistent inflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1611827","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T04:10:38Z","timestamp":1755749438000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Overall hemostatic potential as a marker of subclinical hypercoagulability in treated psoriasis patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Eva Klara","family":"Merzel \u0160abovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeja","family":"Kraner \u0160umenjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Bo\u017ei\u010d Mijovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miodrag","family":"Jani\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/1346-8138.15913","article-title":"Pathophysiology of psoriasis: a review","volume":"48","author":"Yamanaka","year":"2021","journal-title":"J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/1346-8138.14939","article-title":"Increased risk of psoriasis in subjects with abdominal obesity: a nationwide population-based study","volume":"46","author":"Han","year":"2019","journal-title":"J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"829709","DOI":"10.3389\/fcvm.2022.829709","article-title":"Psoriasis increased the risk of adverse cardiovascular outcomes: a new systematic review and Meta-analysis of cohort study","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","article-title":"The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events","volume":"77","author":"Egeberg","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"868277","DOI":"10.3389\/fimmu.2022.868277","article-title":"Psoriasis and cardiovascular diseases: an immune-mediated cross talk?","volume":"13","author":"Orlando","year":"2022","journal-title":"Front Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e18125","DOI":"10.1371\/journal.pone.0018125","article-title":"Psoriasis carries an increased risk of venous thromboembolism: a Danish Nationwide cohort study","volume":"6","author":"Ahlehoff","year":"2011","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1080\/07853890.2021.1942974","article-title":"Venous thrombotic events in psoriasis patients: a systematic review with meta-analysis","volume":"53","author":"Hillary","year":"2021","journal-title":"Ann Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jid.2017.09.021","article-title":"Protection from psoriasis-related thrombosis after inhibition of IL-23 or IL-17A","volume":"138","author":"Li","year":"2018","journal-title":"J Invest Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"13043","DOI":"10.1038\/s41598-021-90684-8","article-title":"Psoriatic disease is associated with systemic inflammation, endothelial activation, and altered haemostatic function","volume":"11","author":"Visser","year":"2021","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e11173","DOI":"10.7759\/cureus.11173","article-title":"Cardiovascular involvement in psoriasis, diagnosing subclinical atherosclerosis, effects of biological and non-biological therapy: a literature review","volume":"12","author":"Valaiyaduppu Subas","year":"2020","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"10402","DOI":"10.3390\/ijms221910402","article-title":"Psoriasis and atherosclerosis\u2014skin, joints, and cardiovascular story of two plaques in relation to the treatment with biologics","volume":"22","author":"Wierzbowska-Drabik","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1055\/s-0030-1265294","article-title":"The overall hemostasis potential: a laboratory tool for the investigation of global hemostasis","volume":"36","author":"Antovic","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"ref14","first-page":"523","article-title":"The overall hemostatic potential (OHP) assay","volume-title":"Methods Mol Biol.","author":"Curnow","year":"2017"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0049-3848(01)00332-2","article-title":"A simple and rapid laboratory method for determination of Haemostasis potential in plasma","volume":"103","author":"He","year":"2001","journal-title":"Thromb Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"368504241287893","DOI":"10.1177\/00368504241287893","article-title":"Arterial function is preserved in successfully treated patients with psoriasis vulgaris","volume":"107","author":"Merzel \u0160abovi\u0107","year":"2024","journal-title":"Sci Prog"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00403-024-03403-4","article-title":"Residual metabolic burden in young psoriasis patients successfully treated with biologics","volume":"316","author":"Merzel \u0160abovi\u0107","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"21438","DOI":"10.1038\/s41598-021-00999-9","article-title":"Biomarkers of subclinical atherosclerosis in patients with psoriasis","volume":"11","author":"Kaiser","year":"2021","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12026-024-09584-4","article-title":"Residual non-specific and disease-specific inflammatory markers in successfully treated young psoriasis patients: a cross-sectional study","volume":"73","author":"Merzel \u0160abovi\u0107","year":"2025","journal-title":"Immunol Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"897733","DOI":"10.3389\/fcvm.2022.897733","article-title":"Increased BMI and blood lipids are associated with a hypercoagulable state in the Moli-sani cohort","volume":"9","author":"de Laat-Kremers","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1182\/blood-2013-05-427708","article-title":"Inflammation, obesity, and thrombosis","volume":"122","author":"Samad","year":"2013","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"688861","DOI":"10.3389\/fimmu.2021.688861","article-title":"Thrombosis in psoriasis: cutaneous cytokine production as a potential driving force of Haemostatic dysregulation and subsequent cardiovascular risk","volume":"12","author":"Visser","year":"2021","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1038\/jid.2009.112","article-title":"The risk of stroke in patients with psoriasis","volume":"129","author":"Gelfand","year":"2009","journal-title":"J Invest Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/ard.2010.147793","article-title":"The association between smoking and the development of psoriatic arthritis among psoriasis patients","volume":"71","author":"Eder","year":"2012","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1611827\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T04:10:40Z","timestamp":1755749440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1611827\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":26,"alternative-id":["10.3389\/fmed.2025.1611827"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1611827","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"article-number":"1611827"}}